Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Viatris Among Three Companies Licensed To Make GSK/Pfizer-Backed Long Acting HIV Prevention Drug

ViiV Healthcare and Medicines Patent Pool (MPP) have signed sublicence agreements with Aurobindo Pharma, Cipla Limited, and Viatris Inc (NASDAQ:VTRS) – through its subsidiary Mylan – to…
byVandana Singh
March 30, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • ViiV Healthcare and Medicines Patent Pool (MPP) have signed sublicence agreements with Aurobindo Pharma, Cipla Limited, and Viatris Inc (NASDAQ:VTRS) – through its subsidiary Mylan – to manufacture generic versions of cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP). 
  • Aurobindo Pharma and Viatris will manufacture in India. 
  • Cipla Limited will manufacture in India and plans to manufacture in South Africa too. 
  • ViiV Healthcare is majority owned by GSK Plc (NYSE:GSK), with Pfizer Inc (NYSE:GSK) and Shionogi as shareholders.
  • GSK said in a statement that approximately 1.5 million people acquired HIV worldwide in 2021, among whom 860,000 live in sub-Saharan Africa. While oral PrEP options are now available in many countries, access to cabotegravir LA for PrEP could significantly contribute to reducing HIV transmission by providing people with a choice in their HIV prevention options.
  • In July 2022, ViiV signed a new voluntary licensing agreement with the Medicines Patent Pool (MPP) for patents relating to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP) for the least developed, low-income, lower-middle-income and Sub-Saharan African countries.
  • The agreement allowed selected generic manufacturers to develop, manufacture and supply generic versions of long-acting cabotegravir for PrEP, the first long-acting HIV prevention medicine, in 90 countries, subject to regulatory approvals.
  • In December 2021, the FDA approved ViiV Healthcare’s Apretude, the first and only long-acting injectable pre-exposure prophylaxis option, to reduce the risk of sexually acquired HIV-1. 
  • The long-acting injectable was approved for use in adults and adolescents weighing at least 35 kg who are at risk of sexually acquiring HIV and have a negative HIV-1 test before initiation.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Cronos Cannabis Co. Will Provide $51M To GrowCo Toward Facility Expansion Fund

By Jelena Martinovic
June 20, 1:04 PM
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) announced on Thursday an expansion of Cronos Growing Company, a cannabis cultivation business that the Toronto-based company owns 50% of.The investment will be funded by a roughly $51 million (CA$70 million) secured non-revolving credit facility provided by Cronos. It will assist GrowCo's expansion of its purpose-built cannabis facility in Leamington, Ontario, that will produce high-quality cannabis flower, the company said in a press release., Under the four-year supply deal between Cronos and GrowCo and prior to the first sale of products from the newly constructed area, Cronos will have the option to buy roughly 80% of GrowCo's production. Once first sales from the newly constructed area occur, Cronos will have the option to purchase 70% of all GrowCo's supplies on an annual basis.

CRON